# US 2025/0164505 A1 · Detection of extracellular vesicle biomarkers for the diagnosis of autism spectrum disorder

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0164505 A1
- Document ID: US20250164505A1
- Status: Published application
- Kind: A1
- Application number: 18/629,294
- Filed: 2024-04-08
- Published: 2025-05-22
- Earliest claimed: 2023-11-20
- Assignees: Qatar Foundation for Education, Science and Community Development
- Applicants: Qatar Foundation for Education, Science and Community Development
- Inventors: Yongsoo Park; Sara Abdulla
- Web page: https://patentgrep.com/patent/US20250164505A1

## CPC

- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 33/5076: {involving cell organelles, e.g. Golgi complex, endoplasmic reticulum}
- G01N 2800/28: Neurological disorders
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

Methods for early diagnosis of autism spectrum disorder, based on detecting certain protein biomarkers associated with plasma extracellular vesicles, are described.

## Claims

### Claim 1

A method for diagnosing autism spectrum disorder comprising
a) isolating extracellular vesicles (EVs) from plasma samples of subjects suffering from autism spectrum disorder; and
b) measuring protein expression levels in the extracellular vesicles.

### Claim 2

A method for diagnosing autism spectrum disorder comprising:
a) isolating extracellular vesicles (EVs) from plasma samples of subjects suffering from autism spectrum disorder;
b) lysing or permeabilizing the EVs; and
c) measuring expression levels of proteins selected from WWP2, CLEC1B, HSP-27, CD40, and/or FR-alpha using an enzyme-linked immunosorbent assay (ELISA);
wherein increased expression of proteins selected from WWP2, CLEC1B, HSP-27, CD40, and/or FR-alpha compared to control is diagnostic of autism spectrum disorder.

### Claim 3 (depends on 1, 2)

The method of claim 1 or claim 2, comprising measuring expression levels of at least one of WWP2, CLEC1B, HSP-27, CD40, and/or FR-alpha.

### Claim 4 (depends on 1, 2)

The method of claim 1 or claim 2, comprising measuring expression levels of at least two of WWP2, CLEC1B, HSP-27, CD40, and/or FR-alpha.

### Claim 5 (depends on 1, 2)

The method of claim 1 or claim 2, comprising measuring expression levels of at least three of WWP2, CLEC1B, HSP-27, CD40, and/or FR-alpha.

### Claim 6 (depends on 1, 2)

The method of claim 1 or claim 2, comprising measuring expression levels of at least four of WWP2, CLEC1B, HSP-27, CD40, and/or FR-alpha.

### Claim 7 (depends on 1, 2)

The method of claim 1 or claim 2, comprising measuring expression levels of WWP2, CLEC1B, HSP-27, CD40, and FR-alpha.

### Claim 8

A method for diagnosing autism spectrum disorder comprising:
a) isolating extracellular vesicles (EVs) from plasma samples of subjects suffering from autism spectrum disorder;
b) lysing or permeabilizing the EVs; and
c) measuring expression levels of proteins selected from Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF, using an enzyme-linked immunosorbent assay (ELISA);
wherein abnormal expression of proteins selected from Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF compared to control, is diagnostic of autism spectrum disorder.

### Claim 9 (depends on 1, 8)

The method of claim 1 or claim 8, comprising measuring expression levels of at least one of Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF.

### Claim 10 (depends on 1, 8)

The method of claim 1 or claim 8, comprising measuring expression levels of at least two of Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF.

### Claim 11 (depends on 1, 8)

The method of claim 1 or claim 8, comprising measuring expression levels of at least three of Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF.

### Claim 12 (depends on 1, 8)

The method of claim 1 or claim 8, comprising measuring expression levels of at least four of Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF.

### Claim 13 (depends on 1, 8)

The method of claim 1 or claim 8, comprising measuring expression levels of at least five of Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF.

### Claim 14 (depends on 1, 8)

The method of claim 1 or claim 8, comprising measuring expression levels of Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF.

### Claim 15 (depends on 8)

The method of claim 8, wherein abnormal expression of proteins selected from Gro-alpha, INF-gamma, IL-15, RANTES, SCGF-beta, and/or VEGF compared to control comprises decreased expression of Gro-alpha and/or RANTES, and/or increased expression of INF-gamma, IL-15, SCGG-beta and/or VEGF.
